TY - JOUR
T1 - Application of bioactive hydrogels combined with dental pulp stem cells for the repair of large gap peripheral nerve injuries
AU - Luo, Lihua
AU - He, Yan
AU - Jin, Ling
AU - Zhang, Yanni
AU - Guastaldi, Fernando P.
AU - Albashari, Abdullkhaleg A.
AU - Hu, Fengting
AU - Wang, Xiaoyan
AU - Wang, Lei
AU - Xiao, Jian
AU - Li, Lingli
AU - Wang, Jianming
AU - Higuchi, Akon
AU - Ye, Qingsong
N1 - Publisher Copyright:
© 2020 [The Author/The Authors]
PY - 2021/3
Y1 - 2021/3
N2 - Due to the limitations in autogenous nerve grafting or Schwann cell transplantation, large gap peripheral nerve injuries require a bridging strategy supported by nerve conduit. Cell based therapies provide a novel treatment for peripheral nerve injuries. In this study, we first experimented an optimal scaffold material synthesis protocol, from where we selected the 10% GFD formula (10% GelMA hydrogel, recombinant human basic fibroblast growth factor and dental pulp stem cells (DPSCs)) to fill a cellulose/soy protein isolate composite membrane (CSM) tube to construct a third generation of nerve regeneration conduit, CSM-GFD. Then this CSM-GFD conduit was applied to repair a 15-mm long defect of sciatic nerve in a rat model. After 12 week post implant surgery, at histologic level, we found CSM-GFD conduit could regenerate nerve tissue like neuron and Schwann like nerve cells and myelinated nerve fibers. At physical level, CSM-GFD achieved functional recovery assessed by a sciatic functional index study. In both levels, CSM-GFD performed like what gold standard, the nerve autograft, could do. Further, we unveiled that almost all newly formed nerve tissue at defect site was originated from the direct differentiation of exogeneous DPSCs in CSM-GFD. In conclusion, we claimed that this third-generation nerve regeneration conduit, CSM-GFD, could be a promising tissue engineering approach to replace the conventional nerve autograft to treat the large gap defect in peripheral nerve injuries.
AB - Due to the limitations in autogenous nerve grafting or Schwann cell transplantation, large gap peripheral nerve injuries require a bridging strategy supported by nerve conduit. Cell based therapies provide a novel treatment for peripheral nerve injuries. In this study, we first experimented an optimal scaffold material synthesis protocol, from where we selected the 10% GFD formula (10% GelMA hydrogel, recombinant human basic fibroblast growth factor and dental pulp stem cells (DPSCs)) to fill a cellulose/soy protein isolate composite membrane (CSM) tube to construct a third generation of nerve regeneration conduit, CSM-GFD. Then this CSM-GFD conduit was applied to repair a 15-mm long defect of sciatic nerve in a rat model. After 12 week post implant surgery, at histologic level, we found CSM-GFD conduit could regenerate nerve tissue like neuron and Schwann like nerve cells and myelinated nerve fibers. At physical level, CSM-GFD achieved functional recovery assessed by a sciatic functional index study. In both levels, CSM-GFD performed like what gold standard, the nerve autograft, could do. Further, we unveiled that almost all newly formed nerve tissue at defect site was originated from the direct differentiation of exogeneous DPSCs in CSM-GFD. In conclusion, we claimed that this third-generation nerve regeneration conduit, CSM-GFD, could be a promising tissue engineering approach to replace the conventional nerve autograft to treat the large gap defect in peripheral nerve injuries.
KW - Dental pulp stem cells
KW - Gelatin methacrylate
KW - Human basic fibroblast growth factor
KW - Large gap
KW - Nerve graft
KW - Peripheral nerve injuries
UR - http://www.scopus.com/inward/record.url?scp=85091250748&partnerID=8YFLogxK
U2 - 10.1016/j.bioactmat.2020.08.028
DO - 10.1016/j.bioactmat.2020.08.028
M3 - 期刊論文
AN - SCOPUS:85091250748
SN - 2452-199X
VL - 6
SP - 638
EP - 654
JO - Bioactive Materials
JF - Bioactive Materials
IS - 3
ER -